https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11883 Wed 11 Apr 2018 10:47:53 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41424 Wed 03 Aug 2022 12:06:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33387 34-weeks gestation; n=8) and gestational age matched preterm (31.6-35.1 weeks; n=8) and term normotensive controls were also compared. Agilent Human miRNA microarray v19 was used to detect up to 2006 miRNAs in four placentae from each group. Statistically different levels of expression were determined and refined using predictive modelling. Placental miRNAs predicted to target RAS mRNAs were identified in three databases. Differences detected on the array were confirmed for some miRNAs by semi-quantitative RT-PCR (qPCR, n=7-8 for all groups). Two differentially expressed miRNAs that were known to target human renal REN mRNA (miR-181a-5p and miR-663) were transfected into human HTR-8/SVneo trophoblast cells to examine their effect on placental REN expression and prorenin levels. In early gestation placentae, 186 miRNAs were differentially expressed compared with term placentae (109 increased, 77 decreased). Thirty of the differentially expressed miRNAs were predicted to target RAS components. In mid-gestation placentae, 117 miRNAs were differentially expressed compared with term placentae (69 increased, 48 decreased). Of these, 19 had RAS mRNAs as predicted targets. Eight miRNAs that were lower in early gestation and predicted to target RAS mRNAs were confirmed by qPCR. All showed an increase during gestation and could influence the transgestational profile of the human placental RAS. Additionally, on the array, three miRNAs predicted to target RAS mRNAs (miR-892c-3p, miR-378c and miR-514b-3p) were overexpressed in placentae from women with late-onset PE (P = 3.6E-10, P = 1.8E-05, P = 5.3E-06; respectively). miR-663, which suppresses renal REN mRNA expression, was overexpressed in early-onset PE placentae as determined by qRT-PCR analysis (P = 0.014). Transfection of miR-181a-5p and miR-663 into HTR-8/SVneo trophoblast cells suppressed REN mRNA expression (p = 0.05) and prorenin protein production (P = 0.001). Data can be found via GEO accession number GSE109832. Further validation that the differentially expressed miRNAs do indeed directly target RAS mRNAs and affect placental development and function is required. This study is limited by the small sample size. Therefore independent validation in a larger cohort is required.]]> Wed 02 Mar 2022 14:28:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47023 Tue 13 Dec 2022 12:58:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45665 n = 9; 8.1%). Women with antepartum eclampsia (n = 58, 42.6%) were more likely to have a preterm birth (P = 0.04). Sixty-three (47.4%) women had pre-eclampsia diagnosed prior to their first eclamptic seizure of whom 19 (30.2%) received magnesium sulphate prior to the first seizure. Nearly all women (n = 128; 95.5%) received magnesium sulphate post-seizure. No woman received prophylactic aspirin during pregnancy. Five women had a cerebrovascular haemorrhage, and there were five known perinatal deaths. Conclusions: Eclampsia is an uncommon consequence of pre-eclampsia in ANZ. There is scope to reduce the incidence of this condition, associated with often catastrophic morbidity, through the use of low-dose aspirin and magnesium sulphate in women at higher risk.]]> Thu 23 Mar 2023 13:59:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20348 Sat 24 Mar 2018 08:02:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29165 Sat 24 Mar 2018 07:35:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4787 Sat 24 Mar 2018 07:20:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22880 Sat 24 Mar 2018 07:12:59 AEDT ]]>